|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 912 East Capitol Street, NE |
Address2 |
|
City | Washington |
State | DC |
Zip Code | 20003 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401105617-36
|
||||||||
|
6. House ID# 447300003
|
TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Elizabeth Karan |
Date | 4/22/2024 6:15:16 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Reimbursement for hemophilia services and treatments in Medicare
Reimbursement for hemophilia services and treatments in Medicaid
Implementation of the Hemophilia SNF Access Act
Coverage for Telehealth Services
Closing the Medicaid coverage gap
Issues related to 1115 Waivers in Medicaid
Medicaid unwinding, the process for redetermination of Medicaid eligibility
Preserving and expanding access to Medicaid
Sickle Cell Disease Comprehensive Care Act (H.R. 1672/S.996)
PROTECT Rare Act (H.R. 6094)
MVP Act (H.R. 2666)
Comments Re: Medicaid; CMS Enforcement of State Compliance with Reporting and Federal Medicaid Renewal Requirements Under Section 1902(t) of the Social Security Act (CMS-2447-IFC)
Comments RE: Notice of Benefit and Payment Parameters for 2025 Proposed Rule (CMS-9895-P).
Comments Re: Proposed Rescission of Association Health Plan Final Rule (RIN 1210-AC16)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ellen |
Riker |
|
|
|
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Implementation of the No Surprises Act
Blood and plasma safety and awareness
Bleeding disorders awareness
Issues related to plasma donation in border states
Issues related to access to residential substance use disorder and mental health facilities for individuals with bleeding disorders
Sickle Cell Care Expansion Act (H.R. 3100/S.1423)
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023 (H.R. 3884/S. 1852)
Menstrual Equity for All Act (H.R. 3646)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Homeland Security - Dept of (DHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ellen |
Riker |
|
|
|
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Implementation of the Affordable Care Act
The HELP Copays Act (HR 830)
Policies related to insurance coverage and COVID-19
Coverage of hemophilia treatments and services in private insurance plans, including the alternative funding model
Safe Step Act (HR 2630 / S 652)
Implementation of the No Surprises Act
Policies related to short-term, limited duration insurance
Comments related to the Mental Health Parity and Addiction Equity Act
Policies related to copay accumulator adjustor programs
Letter to the Committee on Education and the Workforce Request for Information on Employer-Sponsored Insurance and Employee Retirement Income Security Act (ERISA)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Internal Revenue Service (IRS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ellen |
Riker |
|
|
|
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY24 House and Senate Labor-HHS Appropriations bills
FY25 House and Senate Labor-HHS Appropriations bills
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ellen |
Riker |
|
|
|
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ellen |
Riker |
|
|
|
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Hemophilia research, prevention, surveillance and service programs and issues
H.R. 3503/S. 1701 - NIH Clinical Trial Diversity Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ellen |
Riker |
|
|
|
Johanna |
Gray |
|
Intern, Senator Barack Obama |
|
Leslie |
Brady |
|
Health Policy Advisor/Legislative Assistant, Rep. Brian Higgins |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |